Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system by Lee, Jong Bong et al.
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
Lipophilic activated ester prodrug approach for drug delivery to the
intestinal lymphatic system
Jong Bong Leea, Atheer Zgaira,b, Jed Maleca,c, Tae Hwan Kimd, Min Gi Kime, Joseph Alia,
Chaolong Qina, Wanshan Fenga, Manting Chiangf, Xizhe Gaof, Gregory Voroning,
Aimie E. Garcesa, Chun Long Laua, Ting-Hoi Chana, Amy Humea, Tecashanell M. McIntosha,
Fadi Soukarieha, Mohammed Al-Hayalia, Elena Cipollaa,h, Hilary M. Collinsa, David M. Heerya,
Beom Soo Shine, Sun Dong Yooe, Leonid Kaganf, Michael J. Stocksa, Tracey D. Bradshawa,
Peter M. Fischera, Pavel Gershkovicha,⁎
a School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK
b College of Pharmacy, University of Anbar, Anbar 31001, Iraq
c DMPK, Evotec, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK
d College of Pharmacy, Catholic University of Daegu, Gyeongsan 38430, Republic of Korea
e School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
fDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
g Comparative Medicine Resources, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
h School of Pharmacy, Universita di Roma Tor Vergata, Rome 00173, Italy
A R T I C L E I N F O
Keywords:
Lymphatic transport
Prodrugs
Bexarotene
Retinoic acid
Chylomicron
Activated esters
A B S T R A C T
The intestinal lymphatic system plays an important role in the pathophysiology of multiple diseases including
lymphomas, cancer metastasis, autoimmune diseases, and human immunodeﬁciency virus (HIV) infection. It is
thus an important compartment for delivery of drugs in order to treat diseases associated with the lymphatic
system. Lipophilic prodrug approaches have been used in the past to take advantage of the intestinal lymphatic
transport processes to deliver drugs to the intestinal lymphatics. Most of the approaches previously adopted were
based on very bulky prodrug moieties such as those mimicking triglycerides (TG). We now report a study in
which a lipophilic prodrug approach was used to eﬃciently deliver bexarotene (BEX) and retinoic acid (RA) to
the intestinal lymphatic system using activated ester prodrugs. A range of carboxylic ester prodrugs of BEX were
designed and synthesised and all of the esters showed improved association with chylomicrons, which indicated
an improved potential for delivery to the intestinal lymphatic system. The conversion rate of the prodrugs to BEX
was the main determinant in delivery of BEX to the intestinal lymphatics, and activated ester prodrugs were
prepared to enhance the conversion rate. As a result, an 4-(hydroxymethyl)-1,3-dioxol-2-one ester prodrug of
BEX was able to increase the exposure of the mesenteric lymph nodes (MLNs) to BEX 17-fold compared to when
BEX itself was administered. The activated ester prodrug approach was also applied to another drug, RA, where
the exposure of the MLNs was increased 2.4-fold through the application of a similar cyclic activated prodrug.
Synergism between BEX and RA was also demonstrated in vitro by cell growth inhibition assays using lymphoma
cell lines. In conclusion, the activated ester prodrug approach results in eﬃcient delivery of drugs to the in-
testinal lymphatic system, which could beneﬁt patients aﬀected by a large number of pathological conditions.
1. Introduction
The intestinal lymphatic system is an important organ of the im-
mune system as it accommodates more than half of the body's lym-
phocytes [1, 2]. In addition, the intestinal lymphatic system plays an
important role in the pathophysiology of multiple diseases including
lymphomas, metastasis of some solid tumours, and human im-
munodeﬁciency virus (HIV) infection. Therefore, eﬃcient delivery of
drugs to the intestinal lymphatic system has potential to improve
treatment of diseases such as autoimmune disorders, lymphatic system-
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associated cancers, HIV infections and cancer metastasis [3–6]. How-
ever, only a very limited proportion of a drug can usually be distributed
from the systemic circulation into the lymphatic system [4, 7]. As a
result, in order to achieve suﬃcient concentrations of the drugs in the
aﬀected lymph nodes, the required levels in systemic circulation would
be very high and associated with signiﬁcant adverse side eﬀects.
Therefore, there is an unmet need for speciﬁc delivery of therapeutic
agents to the intestinal lymphatics for treatment of patients aﬀected by
diseases associated with the intestinal lymphatic system.
Although most drugs absorbed from the gastrointestinal (GI) system
are passed to the portal vein, lipophilic compounds may also gain ac-
cess to systemic circulation through the intestinal lymphatics [8, 9]
(Fig. 1). This distribution to the lymphatic system is determined mainly
by the association of drugs with large lipoproteins, i.e. chylomicrons
(CM), in the enterocytes. This is because drug molecules need to be
associated with CM in order to utilise them as a carrier to the lymphatic
system. In fact, a linear correlation between drug association with CM
and lymphatic absorption is well established [10].
Intestinal lymphatic transport has been studied previously as an
absorption pathway, with a primary focus on the fact that this ab-
sorption pathway can bypass the liver at the ﬁrst pass following enteric
drug administration, hence decreasing ﬁrst-pass metabolism and
thereby increasing the systemic bioavailability of drugs [11–14].
However, an issue that has been overlooked in the past is that the
lymphatic system has functional importance, and drugs that are trans-
ported by this route can reach very high concentrations in lymph ﬂuid
and lymph nodes, and can therefore exert their pharmacological ac-
tivity within the lymphatic system itself [12]. It is known that if a drug
has the necessary physicochemical properties, an appropriate lipid-
based formulation can facilitate the transport of the drug via the in-
testinal lymphatic system following oral administration [5, 15]. On the
other hand, lipophilic prodrug approaches have been employed in the
past to take advantage of the intestinal lymphatic transport of drug
molecules that otherwise would not have the necessary physicochem-
ical properties required for association with CM. However, previously
suggested approaches were mainly based on glyceride mimetic or very
bulky prodrug moieties [8, 14, 16–18]. It was believed that an alkyl
ester prodrug approach would not be suitable for this purpose because
of the instability of alkyl esters during the absorption phase [8].
We now report a study where a lipophilic prodrug approach was
used to deliver bexarotene (BEX) and retinoic acid (RA) eﬃciently to
the intestinal lymphatic system by a novel activated ester prodrug ap-
proach. Drugs with a wide range of indications and mechanisms of
action could potentially beneﬁt from delivery to the intestinal lym-
phatic system by the proposed approach. Here we focused on delivery
of BEX and RA to potentially improve the treatment outcomes of non-
Hodgkin's lymphoma (NHL) in patients with substantial mesenteric
lymph node (MLN) involvement in the disease. Lymphoma is the most
common cause of mesenteric lymphadenopathy [19]. In as many as
30–50% of NHL patients, especially those with diﬀuse large B-cell
lymphoma (DLBCL), disease signiﬁcantly aﬀects MLNs [6]. This lym-
phadenopathy is persistent even in the disease remission stage, ren-
dering patients susceptible to relapse [19]. In this study, 25 prodrugs of
BEX were synthesised and assessed. The activated ester prodrug was
shown as the most promising approach for eﬃcient delivery to the in-
testinal lymphatic system. This successful approach was further applied
to RA. In addition, our results show that the two drugs exert synergy in
treatment of DLBCL in vitro at concentrations which are realistically
achievable in the lymph nodes, when the suggested delivery approach
is applied in vivo.
2. Materials and methods
2.1. Materials
BEX was purchased from LC Laboratories (Woburn, MA, USA). RA
(all-trans), Intralipid®, esterase from porcine liver, sodium taurocholate
(NaTc), NaCl, NaF and lecithin were obtained from Sigma (Gillingham,
UK). Rat plasma was purchased from Sera Laboratories (West Sussex,
UK). Thiazolyl blue tetrazolium bromide (MTT), sesame oil, poly-
ethylene glycol 400 (PEG400) and all solvents (HPLC grade or higher)
were purchased from Fisher Scientiﬁc (Loughborough, UK).
2.2. Chemical synthesis
2.2.1. General synthetic scheme for esteriﬁcation
Ester prodrugs of BEX and RA were synthesised by adding
2.87mmol of the desired alcohol to 0.287mmol of BEX or RA. 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide (0.431mmol) and 4-di-
methylaminopyridine (0.057mmol) were added, and dichloromethane
(15mL) was used as the solvent. The mixture was stirred magnetically
overnight at room temperature. Puriﬁcation was performed by ﬂash
chromatography using a 200–400 mesh silica gel-packed glass columns
and hexane–ethyl acetate 50:2 (v/v) as the mobile phase. Speciﬁc de-
tails for compounds that were obtained by diﬀerent synthetic schemes
are described in Supplementary Material 1.
2.2.2. Characterisation of synthetic prodrugs
1H NMR and 13C NMR spectra were obtained using a Bruker 400
Ultrashield instrument at 400 and 100MHz, respectively. Bruker
TOPSPIN 2.1 software was used to analyse the spectra. Chemical shifts
are reported as parts per million (ppm) relative to tetramethylsilane
Fig. 1. Schematic diagram of the intestinal lym-
phatic transport pathway. Highly lipophilic drugs
and prodrugs with appropriate physicochemical
properties are able to associate with the chylomi-
crons (CM) in the enterocyte. The drug-CM complex
is too large to penetrate the blood capillaries and
therefore is passed on to the intestinal lymphatic
system before reaching the systemic circulation. GI,
gastrointestinal; BEX, bexarotene; RA, retinoic acid.
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(internal standard) to the nearest 0.01 ppm and coupling constants (J)
to the nearest 0.1 Hz.
2.3. CM and artiﬁcial lipid particle association assay
2.3.1. Preparation of artiﬁcial lipid particle emulsion for in vitro association
studies
To prepare the artiﬁcial lipid particle emulsion, Intralipid® 20%
(Sigma, Gillingham, UK) was diluted using phosphate buﬀered saline
(PBS) to yield 100mg/dL of triglyceride (TG) concentration [15, 20]. A
TG enzymatic kit (Sigma Aldrich, Dorset, UK) was used to monitor the
TG concentration by following manufacturer's instructions.
2.3.2. Preparation of human plasma-derived CM emulsion for ex vivo
association studies
The protocol for preparation of human plasma-derived CM emulsion
was approved by the Faculty of Medicine and Health Sciences Research
Ethics Committee, Queens Medical Centre, Nottingham University
Hospitals (BT12102015 CBS SoP). Healthy male volunteers of
19–40 years old and with body mass index of 18.5–25.0 were enrolled
in the study after providing informed consent. The participants were
excluded if any medication was used within one week prior to enrol-
ment. On the morning of the study, participants received a high-fat
meal (equivalent to a full English breakfast). Between 3 and 4 h fol-
lowing breakfast, 30mL of blood was collected using heparinised tubes
(Vacutainer® Blood Collection Tubes) and centrifuged (800 g, 10 min,
15 °C) to obtain plasma.
CM separation was performed as previously reported with minor
modiﬁcations [10, 15]. Brieﬂy, KBr (0.57 g) was mixed with 4mL of
plasma to yield density of 1.1 g/mL. PBS with densities of 1.006, 1.019,
and 1.063 g/mL were prepared by adding appropriate amounts of KBr.
These PBS of diﬀerent densities were layered on top of the plasma to
build density gradient layers in polyallomer ultracentrifuge tubes. The
samples were then centrifuged at 268,350 g for 35min at 15 °C using an
ultracentrifuge (SORVALL® TH-641 Rotor, Thermo Fisher Scientiﬁc,
UK). Following ultracentrifugation, approximately 1mL of the upper
layer containing CM was collected. TG concentration of CM emulsion
was assessed using the TG enzymatic kit (Sigma Aldrich, Dorset, UK).
TG concentration of the emulsion was adjusted to 100mg/dL by di-
luting with PBS of 1.006 g/mL density. The CM emulsion was stored at
4 °C until the association assay (˂24 h).
2.3.3. Association assay
The association of the compounds with artiﬁcial lipid particle
emulsion and human CM was assessed using previously reported
methodology with minor modiﬁcations [10]. Brieﬂy, 1mL of artiﬁcial
lipid particle or CM emulsions (TG concentration 100mg/dL) was used
for the association assay. The emulsion was spiked with stock solutions
of tested compounds (in acetonitrile) to give a ﬁnal concentration of
1.755 μM. The reaction mixtures were incubated at 37 °C for 1 h with
magnetic stirring at 300 rpm. Following the incubation, density gra-
dient ultracentrifugation was applied as described above to isolate the
artiﬁcial lipid particles or CM associated with the tested compounds
from the rest of the experimental medium. All experiments were con-
ducted in quintuplicates or above.
2.4. Prodrug conversion assay
The prodrugs were tested for their stability and conversion into
their corresponding active drug using fasted state simulated intestinal
ﬂuid (FaSSIF) with added esterase enzyme activity (20 IU/mL), rat
plasma, and postprandial rat lymph [21]. The FaSSIF was prepared as
previously described in the literature [22]. The medium was pre-heated
to 37 °C prior to the assay for 5min. The experiment was initiated by
spiking stock solutions of prodrugs to give a ﬁnal concentration of
10 μM of the prodrugs in the medium. When the stability of the artiﬁcial
emulsion-associated prodrugs was tested in plasma, the association of
compounds with artiﬁcial emulsion was performed prior to stability
experiments and the concentrations of the compounds in the associated
emulsion were measured. The emulsion was then spiked to give a
concentration of 10 μM of the prodrugs in plasma. The reaction mix-
tures were incubated at 37 °C and shaken at 200 rpm on a temperature-
controlled orbital shaker (Thermo Scientiﬁc MaxQ4000, Waltham, MA,
USA) for 4 h. Samples were withdrawn at pre-determined time points,
and the reaction was terminated by addition of acetonitrile. The sam-
ples were then subjected to sample preparation and analysis as de-
scribed below. The natural log percentage of the prodrug concentration
was plotted against incubation time, and the slope (k) was obtained
from the plot. Half-life of active drug release (t1/2) was calculated by
the following equation: t1/2=−0.693/k. All experiments were con-
ducted in triplicate.
2.5. Animal experiments
2.5.1. Animals
The protocols for pharmacokinetic and biodistribution experiments
in this study were reviewed and approved by the University of
Nottingham Ethical Review Committee in accordance with the Animals
[Scientiﬁc Procedures] Act 1986. Male Sprague Dawley rats (Charles
River Laboratories, UK) weighing 350–380 g were used. The animals
were housed in the Bio Support Unit, University of Nottingham.
Continuous lymph collection was performed according to a protocol
approved by the Institutional Animal Care and Use Committee at
Rutgers, The State University of New Jersey. Male Sprague Dawley rats
(Envigo, Inc., NJ, USA) weighing 300–350 g were used for the con-
tinuous lymph collection. Animals were allowed free access to food and
water and were acclimatised for at least 6 days prior to any procedures
at both institutions in a controlled-temperature environment with 12 h
light/dark cycles.
2.5.2. Pharmacokinetic study
Jugular vein cannulation surgery procedures were conducted under
general anaesthesia for blood sampling. The animals were allowed two
days to recover following surgery and were fasted up to 12 h prior to
experiments with free access to drinking water. Formulations were
prepared at concentrations equivalent to 2.5 mg/mL and 10mg/mL of
active drug for intravenous and oral administration, respectively.
Solutions of the tested compounds in PEG400 were used as the dosing
vehicle for intravenous administration. For oral administration, all
prodrugs were administered as a solution in sesame oil to stimulate
intestinal lymphatic transport [15]. For oral administration of BEX and
RA, oral gavage of sesame oil was administered prior to administration
of BEX or RA solution in PEG400 due to low solubility of the two
compounds in TG. In the lipid-free group BEX was administered orally
formulated as a solution in PEG400. The formulations were adminis-
tered by an oral gavage for oral administration or via the jugular vein
cannula followed by 0.3mL heparinised saline (50 IU/mL) for in-
travenous injection. Blood samples of 250 μL volume were collected
from the cannula at pre-determined time points following administra-
tion. NaF (10mg/mL) was used as an anticoagulant and inhibitor of
esterase activity. Blood samples were centrifuged at 3000 g for 10min
to obtain plasma.
2.5.3. Biodistribution study
Formulations were prepared as described in the above pharmaco-
kinetic study and were delivered by an oral gavage. Animals were eu-
thanised at pre-determined time points. Blood was collected from the
posterior vena cava and lymph samples were taken from the mesenteric
lymph duct. MLNs were dissected and collected as previously described
[5, 23]. The MLNs were isolated from surrounding tissue with care not
to compromise the integrity of the lymph nodes. The MLNs were
homogenised (POLYTRON® PT 10–35 GT, Kinematica AG, Luzern,
J.B. Lee et al. Journal of Controlled Release 286 (2018) 10–19
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Switzerland) with 10mg/mL NaF in water (1,2, w/v) on an ice bath
prior to sample preparation for HPLC analysis.
2.5.4. Postprandial continuous lymph collection
Surgical and experimental procedures for lymph collection were
performed as previously described with minor modiﬁcations [24].
Peanut oil (2 mL) was orally administered to the animals 1–2 h prior to
surgery. The thoracic duct was cannulated and the cannula was ex-
teriorised under the skin to the back of the neck under general anaes-
thesia. The rats were allowed to recover for 24 h before collection and
gel-based food and water were provided during recovery and lymph
collection. Postprandial lymph was collected continuously through the
extension tubing into a tube kept on ice.
2.6. TG solubility measurement
Compounds were dissolved in fresh aliquots of sesame oil in ex-
cessive amounts in glass vials (in triplicate) and stirred using a mag-
netic stirring bar at 37 °C for 72 h. The mixture was then ﬁltered by
centrifugation in a Costar Spin-X Centrifuge Tube (Fisher Scientiﬁc,
Loughborough, UK) at 2400 g for 5min. The ﬁltrates were analysed for
concentration of the tested compounds by means of HPLC.
2.7. Analytical methods for determination of concentrations of BEX, RA
and their prodrugs in biological samples
2.7.1. Sample preparation
A combination of protein precipitation and liquid-liquid extraction
was applied to samples prior to HPLC injection. To 100 μL sample,
300 μL of acetonitrile was added for protein precipitation and then
300 μL of pH modiﬁer was added when necessary (Supplementary
Material Table S2). Liquid-liquid extraction was achieved with hexane
(3mL) by vortex-mixing for 10min and centrifugation at 1160 g for
5min. The organic layer was separated and evaporated under N2 gas.
Reconstitution solvent (100 μL) was used as detailed in Supplementary
Material Table S2 and 40 μL was injected into the HPLC-UV system. The
stability of the prodrugs was preliminarily tested in plasma supple-
mented with 10mg/mL NaF for 3 h at room temperature and 24 h at
−20 °C, demonstrating that they were stable at these conditions
(> 90% stability). Therefore, storage and preparation of all samples
were performed within the time frame and conditions of conﬁrmed
stability.
2.7.2. Analytical conditions
The HPLC-UV system consisting of a separation module (Waters
Alliance 2695) equipped with a UV detector (Waters 996) was used for
analysis. Samples in the autosampler were maintained at 4 °C and the
column at 40 °C. The stationary and mobile phases were used as spe-
ciﬁed in Supplementary Material Table S2. BEX and its prodrugs were
detected at 259 nm and RA and its prodrugs at 357 nm.
2.8. Cell growth inhibition assay
DLBCL cell lines of DOHH2 and VAL were obtained from the Gene
Regulation and RNA Biology group in University of Nottingham. Cell
growth inhibition was assessed by MTT assay with a minor modiﬁcation
from previously reported methods [25–27]. Cells were seeded at a
density of 2000 cells/well and allowed to adapt overnight. Test com-
pounds were serial-diluted with dimethyl sulfoxide (DMSO) and spiked
on the next day to yield 0.1% (v/v) DMSO. Control wells were treated
with 0.1% DMSO vehicle alone. At the time of drug addition, separately
prepared wells were processed for Tzero readings as previously de-
scribed [27]. The treated cells were incubated further for 72 h at 37 °C
and processed for cell growth assessments.
2.9. Statistical analyses
Assessment of statistical signiﬁcance of diﬀerences between two
groups was conducted by means of two-tailed unpaired t-test. Statistical
signiﬁcance among three or more groups was assessed by means of a
one-way ANOVA followed by Tukey's multiple comparisons test.
Statistical signiﬁcance was declared when a p-value was lower than
0.05. The analyses were performed on GraphPad Prism version 7.01
(GraphPad Software, Inc., La Jolla, CA, USA). The concentrations that
inhibited cell growth by 50% (GI50) were also calculated using
GraphPad Prism and isobole plots were presented following a pre-
viously reported method to assess synergy between BEX and RA [28].
Pharmacokinetic parameters were calculated by non-compartmental
analysis using Phoenix WinNonlin 6.3 software (Pharsight, Mountain
View, CA, USA).
3. Results
3.1. Preparation of prodrugs of BEX
A total of 25 prodrugs of BEX were designed in silico to possess the
necessary physicochemical properties needed for association with CM
and therefore high potential for the intestinal lymphatic transport fol-
lowing oral administration [20]. All prodrugs were then successfully
synthesised and puriﬁed (Fig. 2; compound characterisation in Sup-
plementary Material 1). Prodrugs 1–18 were the ﬁrst generation of
candidate compounds which were originally synthesised and tested.
The activated ester prodrugs 19–25 were then developed to introduce
improvement to the ﬁrst generation candidate compounds.
3.2. Association of BEX and its prodrugs with lipoproteins
The association of drugs with CM in the enterocytes is the key
process that determines whether they can be delivered via the intestinal
lymphatic transport pathway. Therefore the association was tested in
vitro using artiﬁcial CM-like emulsion prepared from Intralipid®, as well
as ex vivo using plasma-derived human CM. As shown in Fig. 3a and
Supplementary Material Fig. S1, all prodrugs of BEX had higher asso-
ciation with CM than BEX (p < .05), indicating improved potential for
delivery to the intestinal lymphatic system. The diﬀerence in aﬃnity of
compounds for the artiﬁcial emulsion versus natural human CM was not
statistically signiﬁcant for most prodrugs, except for prodrugs 20 and
24 (Supplementary Material Fig. S1). The correlation between the in
vitro and ex vivo assessments demonstrated an R2 value of 0.694 (Sup-
plementary Material Fig. S2). Intralipid® is a lipid emulsion mostly
consisting of TG, and therefore the similarity in association suggests
that the aﬃnity to TG is the most important factor in the association of
compounds with CM. However, prodrugs 20 and 24 showed signiﬁcant
diﬀerences (Supplementary Material Fig. S1), which indicates that
surface apolipoproteins may play a role in association with CM at least
for some molecules [20].
3.3. Conversion of BEX prodrugs to BEX
The active moiety should be released from the prodrug within the
lymphatic system in order to achieve pharmacological eﬀect on targets
in the lymphatic system. In this work the candidate prodrugs were
tested for their stability and in vitro conversion to the active drug (BEX)
in rat plasma, which represented a reasonable surrogate for the enzy-
matic release of BEX upon reaching the intestinal lymphatic system
(Fig. 3b and Supplementary Material Fig. S3). Since the main interest of
this study is delivery of active drug to the intestinal lymphatic system, it
would be, in theory, ideal to assess release of the active moiety directly
in intestinal lymph ﬂuid for all prodrug candidates. However, since we
had above 25 prodrug candidates in this work, there are practical
limitations of lymph volume that can be collected, which would result
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in excessive number of animals required, as well as technical and
ethical issues associated with lymphatic cannulation surgery. Although
slightly lower protein binding has been observed in lymph compared to
plasma for some drugs, it is known that the composition and levels of
enzymes in the lymph ﬂuid is similar to those in blood [29, 30].
Therefore, rat plasma was chosen as a surrogate model to initially
screen candidate prodrugs for the enzymatic release of the active
moiety.
The in vitro conversion of the prodrugs was also tested in FaSSIF
with added esterase enzyme activity (Fig. 3b and Supplementary Ma-
terial Fig. S3), which is representative for release of the active drug
from the prodrugs in the GI environment prior to absorption. All pro-
drugs had an ester bond which can be cleaved by esterases to release
BEX. In both rat plasma and FaSSIF with esterase, the degradation of
prodrugs corresponded to generation of BEX and no other product
peaks were apparent in the HPLC-UV chromatograms at a wavelength
of 259 nm upon bioanalysis, indicating direct biotransformation of the
prodrugs to BEX. Therefore, the half-lives shown in Fig. 3b and Sup-
plementary Material Fig. S3 represent the stability and conversion rate
of the prodrugs to BEX. Prodrugs 10–13 did not degrade and did not
release BEX in either medium within the time frame tested, therefore
they were not included in the graph. The prodrugs 9 and 18 are the
bulkiest compounds included in Supplementary Material Fig. S3, and
probably for this reason their conversion in FaSSIF with esterase was
too slow to be detected during the experiment, and hence half-life could
not be calculated.
3.4. Selection of ﬁrst generation prodrug candidates for in vivo studies
The criteria for selection of prodrug for further development in this
work was high association with CM, good stability in the GI tract prior
to absorption and immediate release of the active drug once it reaches
the intestinal lymphatics. That being said, it was noted that drugs can
still be orally bioavailable even with a relatively short half-life in GI
ﬂuids [31]. In addition, lipid-based formulations can hinder enzymatic
reactions in the GI tract [32]. Therefore, two main properties, including
high CM association and short half-life of active drug release in rat
plasma were considered as the main attribute in prodrug selection.
Among the ﬁrst generation prodrugs (prodrugs 1–18, before prodrugs
19–25 were designed), prodrug 2 (ethyl ester prodrug of BEX) was
selected for further in vivo studies. In addition, prodrug 13 was also
selected for comparison purpose because it is a triglyceride-mimetic
prodrug, an approach that was commonly used by other groups [16,
17].
3.5. Plasma pharmacokinetics and biodistribution of BEX and selected
prodrugs
The in vivo pharmacokinetic and biodistribution proﬁles of BEX and
its prodrugs were assessed following intravenous and oral administra-
tion in rats. When prodrugs were administered, the samples were
analysed for concentrations of both the prodrug and BEX released from
the prodrug. Fig. 4 shows plasma pharmacokinetic proﬁles following
intravenous administration. Prodrug 2 was rapidly converted to BEX in
Fig. 2. Chemical structures of bexarotene (BEX) and its prodrugs.
Fig. 3. Screening and selection of prodrug can-
didates for subsequent in vivo studies. (a)
Association of bexarotene (BEX) and its prodrugs
selected for in vivo studies with human chylomicrons
(CM) mean ± SD, n=5). (b) Half-lives of active
drug release from prodrugs of bexarotene (BEX) se-
lected for in vivo studies in rat plasma and fasted
state simulated intestinal ﬂuid (FaSSIF) with added
esterase activity (20 IU/mL) (mean ± SD, n=3).
BEX was not released from prodrug 13. Full
screening of all tested prodrugs including association
with natural CM, artiﬁcial CM-like emulsion and
stability in simulated intestinal ﬂuid and plasma is
shown in Supplementary Material (Fig. S1 and S3). *,
p < .05.
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plasma and there was no statistically signiﬁcant diﬀerence between
elimination half-lives (t1/2) of BEX following administration of BEX and
the prodrug 2. Fig. 5 shows plasma concentration-time proﬁles and
biodistribution of BEX and its prodrugs following oral administration.
Neither the plasma concentration-time proﬁles nor the pharmacokinetic
parameters (Table 1) diﬀered for BEX between lipid-free and lipid-
coadministered groups following oral administration. The oral bioa-
vailability values (Foral) of BEX following administration of BEX or each
prodrug was calculated based on the intravenous administration proﬁle
of BEX obtained previously [33]. The bioavailabilities of BEX did not
diﬀer signiﬁcantly between administration of BEX itself and adminis-
tration of prodrugs (p > .05). The results of our study suggest that
lymphatic transport has not changed the total amount of BEX absorbed
but instead the drug absorbed into the enterocyte is re-routed to the
intestinal lymphatics by association with CM. For assessment of bio-
distribution to the intestinal lymphatics following oral administration,
the two sampling time points were considered as the most important for
each compound in assessment of lymphatic transport: tmax observed in
plasma and 1 h before tmax. This was based on our previous reports
showing that the concentration of drugs in the intestinal lymphatics
Fig. 4. In vivo pharmacokinetic proﬁles of bexarotene (BEX) and its prodrugs following intravenous administration in rats. BEX or prodrugs 2 and 25 were ad-
ministered at doses equivalent to 2.5 mg/kg of BEX (mean ± SD, n=3 each). Pharmacokinetic proﬁle of BEX following intravenous administration of BEX has been
previously reported by our group [33] and is shown here for comparison.
Fig. 5. In vivo pharmacokinetic and biodistribution proﬁles of BEX and its prodrugs following oral administration in rats. BEX or prodrugs 2, 13 and 25 were
administered at doses equivalent to 10mg/kg of BEX (mean ± SD, n=5 for plasma and n=4 for mesenteric lymph nodes (MLN) and lymph).
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could actually be higher prior to the tmax observed in plasma [5]. Ad-
ditionally, tissues were harvested following the pharmacokinetic stu-
dies, which provided samples at 12 h time point.
Substantial delivery of prodrug 2 to the intestinal lymphatics was
achieved (Fig. 5): the obtained concentrations were 41- and 6.0-fold
higher in lymph and MLNs, respectively, compared to plasma. On the
other hand, the concentrations of BEX released from prodrug 2 were
comparable between the three matrices including MLNs, lymph and
plasma. The results therefore demonstrate that the aﬃnity of prodrug 2
to CM was suﬃcient to deliver considerable concentrations of the
prodrug 2 to the intestinal lymphatics but the conversion rate was not
high enough to yield high concentrations of BEX in the lymphatic
system.
The in vivo assessment of prodrug 13 also showed no substantial
intestinal lymphatic delivery of BEX (Fig. 5): the concentrations of BEX
released from prodrug 13 in MLNs and lymph were found to be com-
parable to that in plasma. For prodrug 13, only BEX was detected while
the intact form of prodrug 13 was not found in any sample at any time
point. This is consistent with a previous study which showed that TG-
mimetic prodrugs are hydrolysed in the intestine before absorption and
subsequent re-synthesis occurs in the enterocytes to yield TG-related
molecules [16]. Conversion of prodrug 13 was not observed in rat
plasma in vitro, but still in vivo it yielded levels of BEX in the intestinal
lymphatics comparable to that in plasma (Fig. 5). This likely indicates
that conversion of prodrug 13 to BEX would rely on lipase enzymes in
the intestinal lumen (recognising the molecule as TG) rather than es-
terase-mediated release of BEX in plasma.
3.6. Development and assessment of activated ester prodrugs of BEX
Following the in vivo assessment results of prodrugs 2 and 13,
second generation activated ester prodrugs of BEX were designed and
synthesised (19–25). It was thought that the release of BEX from the
prodrugs need to be facilitated in order for the levels of BEX in the
intestinal lymphatics to be signiﬁcantly higher than in plasma. For the
activated ester prodrugs, the recognition sites for the enzymes are away
from the main scaﬀold thereby reducing steric hindrance of the enzy-
matic cleavage [34]. Indeed, most of these molecules showed higher
rates of release of active drug (BEX) compared with the ﬁrst generation
prodrugs (Fig. 3b). Among these activated ester candidates, prodrug 25
was selected to proceed to in vivo studies due to its high aﬃnity for CM
(Fig. 3a) combined with the large diﬀerence between half-lives of active
drug release in rat plasma and FaSSIF with esterase (Fig. 3b). Although
prodrug 20 was also considered as a possible candidate, its low TG
solubility (2.67 ± 0.06mg/mL) precluded progress to in vivo studies.
This is because the prodrugs needed to be formulated in lipid-based
formulations which consist of mainly long-chain TG in order to stimu-
late the physiological process of intestinal lymphatic transport.
In vivo studies with prodrug 25 showed that it indeed released
higher levels of free BEX in the intestinal lymphatic system compared to
prodrugs 2 and 13 (Fig. 5). Although the concentrations of prodrug
were still higher than those of BEX, the concentration of BEX achieved
in MLNs was signiﬁcantly higher than in plasma when prodrug 25 was
administered (3.1-fold). In fact, this concentration of BEX in MLNs
achieved by administration of prodrug 25 was 17-fold higher than that
achieved by administration of BEX itself (Fig. 6). This result demon-
strated that enhanced release of BEX from the activated ester prodrug
signiﬁcantly improved delivery of BEX to the MLNs.
3.7. Prodrug conversion in postprandial lymph
It has been noted that there are diﬀerences between the release of
BEX by the prodrugs in rat plasma in vitro and intestinal lymphatics in
vivo. In rat plasma in vitro, the half-lives of active drug release of pro-
drugs 2 and 25 were 20 and 8min, respectively, but contrary to this
rapid conversion, the release of BEX in the intestinal lymphatics in vivo
seemed to be slower. Therefore, it was thought that the release of BEX
in the intestinal lymphatic system in vivo was slower than the release in
vitro in rat plasma. We hypothesised that association of the prodrugs
with lipoproteins could partially hinder their conversion, as the asso-
ciated form would be passed on to the intestinal lymphatics. To test the
hypothesis, we tested the stability of prodrugs in rat plasma, after in-
corporating them into lipid particles in the artiﬁcial emulsion prepared
from Intralipid®. We indeed observed that emulsion-associated forms of
the prodrugs exhibited delayed conversion in plasma (Fig. 7). We also
collected postprandial lymph from rats and tested stability of these
prodrugs. The half-lives of active drug release of prodrugs 2 and 25
obtained in postprandial lymph were prolonged similarly to the
Table 1
Plasma pharmacokinetic parameters of BEX following administration of BEX or its prodrugs by i.v. and p.o. administration (mean ± SD, n=3 for i.v. and n=5 for
p.o.)
Compound dosed BEX 2 25 13
Route of administration p.o. (lipid-free) p.o. (lipid-based) i.v. p.o. i.v. p.o. p.o.
AUCinf (h·ng/mL) 5836 ± 2140 6618 ± 1312 4614 ± 653 8645 ± 2598 5448 ± 301 5976 ± 1407 6887 ± 3821
AUC0→t (h·ng/mL) 4907 ± 1787 5664 ± 1763 4443 ± 628 7751 ± 1552 5178 ± 182 5610 ± 1394 6538 ± 3956
C0 or Cmax (ng/mL) 899 ± 338 1099 ± 432 2860 ± 189 1589 ± 360 4953 ± 614 1306 ± 464 1502 ± 1026
t1/2 (h) 3.0 ± 0.7 3.7 ± 1.2 1.6 ± 0.1 2.7 ± 1.0 1.8 ± 0.3 2.6 ± 0.4 2.5 ± 1.2
Foral (%)a 26.5 ± 9.6 30.6 ± 9.5 – 41.8 ± 8.4 – 30.3 ± 7.5 35.3 ± 21.4
AUCinf, area under the curve from time zero to inﬁnity; AUC0➔t, area under the curve from time zero to the last sampling time point; C0, concentration extrapolated to
time zero; Cmax, maximum observed concentration; t1/2, half-life; Foral, oral bioavailability.
a Calculated based on the AUC0➔t obtained following intravenous administration of BEX at 2.5 mg/kg [33].
Fig. 6. Maximum concentration of bexarotene (BEX) observed in mesenteric
lymph nodes (ng/g) during biodistribution studies following oral administra-
tion of BEX or prodrugs 2, 13 and 25 (mean ± SD, n=4). **, p < .01; ***,
p < .001.
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lipoprotein-associated forms in plasma, which could be due to asso-
ciation of the prodrugs with the very high number of CM present in the
postprandial lymph (Fig. 7). This was further conﬁrmed by the TG
measurements in each test medium (Supplementary Material Table S1).
Taken together, these results likely indicate that association with CM
delays enzymatic conversion of the prodrugs in the intestinal lympha-
tics in vivo but does not prevent the release completely.
3.8. Application of the prodrug approach to intestinal lymphatic delivery of
RA
The prodrug approaches which resulted in successful intestinal
lymphatic transport of BEX were applied to another drug, RA. Two lead
prodrug candidates were synthesised: ethyl ester, 26 and cyclic ester,
27 (Fig. 8a). Both prodrugs 26 and 27 showed improved association
with artiﬁcial emulsion and natural human CM compared with RA
(Fig. 8b). The conversion rate of prodrug 27 to RA was faster than that
of prodrug 26, which was consistent with prodrugs 2 and 25 of BEX
(Fig. 8c), and therefore prodrug 27 was selected as the lead RA prodrug
for subsequent in vivo studies. RA and prodrug 27 were tested in vivo for
plasma pharmacokinetics and biodistribution to the intestinal lym-
phatics following oral administration in conditions which facilitate
lymphatic transport (Fig. 8d). The successful delivery of the prodrug 27
to the intestinal lymphatics and the release of RA resulted in 2.4-fold
higher concentration of RA in MLNs compared to when RA itself was
administered orally at equivalent doses (Fig. 8e). On the other hand,
similar to the case of BEX and its prodrugs, the plasma AUCs of RA
obtained following administration of RA and prodrug 27 did not diﬀer
signiﬁcantly (3313 ± 1846 and 2541 ± 540 h·ng/mL, respectively,
p > .05).
In addition, the anticancer eﬀects of RA and BEX, separately and
combined, were assessed by MTT assay using DLBCL cell lines.
Signiﬁcantly reduced GI50 values of BEX when it was co-administered
with RA demonstrated improved potency and synergy of BEX and RA in
DLBCL (Supplementary Material 2 and Supplementary Material Fig.
S4).
4. Discussion
In this study the lipophilic ester prodrug approach was applied to
deliver drugs selectively to the intestinal lymphatics. Systemic treat-
ment usually struggles to deliver suﬃciently high concentration of
drugs into the intestinal lymphatics where many immune system-
related diseases prevail [4, 7]. The concept underlying the lipophilic
prodrug approach for eﬃcient and selective lymphatic delivery was to
take advantage of the physiological process of intestinal lymphatic
absorption of dietary lipids from the GI tract. Lipophilic prodrugs of
BEX had substantially higher association with CM compared with BEX,
which was essential in this study as association with CM determines the
extent of intestinal lymphatic transport [10]. The diﬀerence between
log P and log D7.4, i.e. the eﬀect of ionisation upon lipophilicity of
compounds at pH 7.4, has previously been discussed as the most critical
physicochemical property aﬀecting the aﬃnity to CM [20]. The BEX
prodrugs studied here are carboxylic acid esters that are not ionisable
(prior to hydrolysis), thus resulting in signiﬁcantly improved associa-
tion.
It should be noted that the lipophilic prodrug approach for delivery
to intestinal lymphatics has been utilised in a limited number of pre-
vious studies [12]. However, much of the previous research employed
TG-mimetic or long-chain fatty acid prodrug moieties in order to
maximise lymphatic transport [8, 14, 16–18]. In the current work we
have also included TG-mimetic or long-chain fatty acid prodrug moi-
eties (10−13), which indeed resulted in high association with CM
(Fig. 3a and Supplementary Material Fig. S1). However, it was re-
markable in our study that prodrugs with short-chain prodrug moieties
(1, 2 and 4) exhibited equally high aﬃnity to CM, which indicated
comparable potential for selective delivery to the intestinal lymphatics.
The stability of the prodrugs tested using rat plasma showed that
hydrolysis of the ester bond was the main metabolic pathway. The
decrease of prodrug concentration directly corresponded to the increase
of active drug (BEX) concentration and no other metabolites of the
prodrugs were observed in the chromatograms. A range of half-lives of
active drug release was obtained from various prodrugs (Fig. 3b and
Supplementary Material Fig. S3) which revealed structure-activity re-
lationships: 1) the length and bulkiness of prodrugs correlated with
prolonged half-lives, consistent with previous reports [35]; 2) com-
parison between prodrugs 2vs.3 and 15vs.16 showed that further sub-
stitution of the methylene group at position 1 of the prodrug moiety
increased prodrug stability, also consistent with previous reports [36].
The plasma pharmacokinetic proﬁles and biodistribution of BEX to
MLNs following oral administration of BEX itself were not aﬀected by
the presence of lipids and the concentrations in MLNs were lower than
those in plasma (Fig. 5). This indicated that BEX itself had no intestinal
lymphatic transport when it was administered orally in conditions
which facilitate lymphatic absorption. Prodrug 2 had signiﬁcantly
higher association with CM than BEX and therefore resulted in sub-
stantially higher concentration in the intestinal lymphatics (MLNs and
lymph) compared to plasma. Nevertheless, the release of BEX from the
prodrug 2 was not suﬃciently rapid so that the concentrations of BEX
itself in the intestinal lymphatics were comparable to that in plasma.
Findings following administration of prodrug 13 were similar to those
of prodrug 2 and therefore we moved on to design second generation
(activated ester) prodrugs which could potentially release the active
drug at a higher conversion rate.
The activated ester prodrugs of BEX (19–25) were therefore de-
signed to provide more extensive liberation of BEX. Unlike the ﬁrst
generation prodrugs (1–18), the ‘outer’ bond is recognised by the en-
zyme instead of the carboxyl ester bond which then subsequently leads
to spontaneous liberation of the carboxylic acid [34]. Accordingly,
these prodrugs could achieve faster conversion into BEX in vitro (Fig. 3b
and Supplementary Material Fig. S3) and consequently higher release of
BEX in the intestinal lymphatics in vivo, in the case of prodrug 25
(Fig. 5). As a result, the maximum concentration of BEX achieved in the
MLNs following oral administration of prodrug 25 was 17-fold higher
than that achieved following administration of BEX itself (Fig. 6). It
should be emphasised that the MLNs are the physiological compartment
of interest as this is where the relevant cancerous cells reside, HIV hides
and replicates, and lymphadenopathy persists [3–6].
The prodrug approach was additionally applied to RA. Similar to
Fig. 7. Detailed bio-relevant assessment of stability of prodrugs 2 and 25 mi-
micking various in vivo situations (mean ± SD, n=3). Bars in orange vertical
stripes represent stability of prodrugs when they are spiked in free form. Bars in
blue horizontal stripes represent stability of prodrugs when they are spiked in
the form of drug-chylomicron (CM) complex. Bars in purple diagonal stripes
represent stability tested ex vivo with CM-rich postprandial lymph. **, p < .01.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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BEX, RA also possesses a carboxylic acid group and derivatisation of
this group resulted in loss of ionisability of the compound, which en-
hanced association with CM (Fig. 8). The 2.4-fold increased con-
centration of RA achievable by administration of prodrug 27 demon-
strated that the activated ester prodrug approach could be applied to
also deliver RA selectively to the intestinal lymphatics. In addition, the
synergistic anticancer eﬀects of BEX and RA were demonstrated in
DLBCL cell lines (Supplementary Material Fig. S4). BEX is a known
speciﬁc agonist for retinoid X receptor (RXR) and all-trans RA is a
speciﬁc agonist for the RA receptor (RAR) [37]. These receptors need to
dimerise in order to exert their pharmacological eﬀects and RXR can
hetero-dimerise with RAR or peroxisome proliferator-activated receptor
(PPAR) to regulate cell proliferation and diﬀerentiation [38]. Hetero-
dimerisation between RXR-PPAR leads to cell proliferation whereas
RXR-RAR hetero-dimers can evoke anti-proliferative eﬀects and apop-
tosis [37]. The synergism between BEX and RA has not been reported
previously and here we demonstrate that such synergism between the
two drugs exists. Therefore, delivering both BEX and RA eﬃciently and
selectively to the intestinal lymphatic system adopting an activated
ester approach can potentially result in better treatment for people
aﬀected by DLBCL, especially when there is signiﬁcant involvement of
MLNs in the disease.
In this study, we report speciﬁc delivery of drugs to the intestinal
lymphatics utilising the lipophilic prodrug approach. It had been pre-
viously stated that simple ester prodrugs would not be very eﬃcient in
enhancing intestinal lymphatic transport [8]. Indeed, lymphatic trans-
port of BEX and RA prodrugs did not alter the overall bioavailability of
the respective active drugs. However, our aim was to change the
paradigm of intestinal lymphatic transport from increasing bioavail-
ability to delivering high concentrations of the active drug to the in-
testinal lymphatic compartments. For this purpose, the suitable pro-
drugs proved to be ones that modify the physicochemical properties to
increase the aﬃnity to CM, while also readily releasing the active drug
upon reaching the lymphatics. This was eﬀectively accomplished by
simple esteriﬁcation, but required activated esters for enhanced release
of the active moiety within the intestinal lymphatic system. The lack of
change in the overall bioavailability of the active drug is in fact a
substantial beneﬁt for anticancer agents, as increased systemic ex-
posure could lead to increased toxicity and side eﬀects. It highlights the
signiﬁcance of prodrug 25, since it increased exposure of the MLNs to
BEX by 17-fold while maintaining the overall systemic bioavailability.
It should be noted that in previous studies when TG mimetics or long
chain fatty acids were used as prodrug approaches to deliver the drug
into the intestinal lymphatics, the fold-increase in concentration
achieved in MLNs was comparable to the prodrug 13 in this study, and
substantially lower than what has been achieved by the activated ester
approach (prodrug 25) [16].
5. Conclusion
We herein report an activated ester lipophilic prodrug approach to
deliver eﬃciently and selectively BEX and RA to the intestinal lym-
phatics. These two drugs have been demonstrated to exert synergistic
growth inhibitory eﬀects in vitro if delivered simultaneously. Prodrugs
of a various range of physicochemical properties with diﬀerent chain
lengths and bulkiness were synthesised and assessed for delivery of the
Fig. 8. Application of the prodrug approach to RA (retinoic acid). (a) Chemical structures of RA and its prodrugs. (b) Association with human chylomicrons and
artiﬁcial emulsion (mean ± SD, n=6). (c) Half-life of active drug release in rat plasma and fasted state simulated intestinal ﬂuid (FaSSIF) with esterase
(mean ± SD, n=3). (d) In vivo pharmacokinetic and biodistribution proﬁles in plasma and intestinal lymphatics following oral administration of RA (10mg/kg) or
prodrug 27 (at equivalent to 10mg/kg RA) in rats (mean ± SD, n=5 for plasma and n=4 for mesenteric lymph nodes (MLN) and lymph). (e) Maximum
concentration of RA observed in MLN (ng/g) during biodistribution studies following oral administration of RA and prodrug 27 (mean ± SD, n= 4). *, p < .05.
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active drug to the intestinal lymphatics. The ﬁndings indicate that
commonly used long-chain fatty acid prodrugs and TG mimetic pro-
drugs might not be the most eﬃcient in delivering the active drug to the
intestinal lymphatic system. However, we found that activated esters
which promote conversion are very eﬃcient for the purpose of delivery
to and release of the active drug within the intestinal lymphatic system.
The approach of activated ester prodrugs could beneﬁt patients aﬀected
by a large number of pathological conditions with involvement of the
intestinal lymphatics in the disease.
Conﬂict of interest
The authors declare that they have no conﬂicts of interest.
Acknowledgments
This work was supported by the Wellcome Trust [grant number
201937/Z/16/Z] and the University of Nottingham - School of
Pharmacy. DOHH2 and VAL cells were gifts from Prof. Martin Dyer,
University of Leicester, to the Gene Regulation and RNA Biology group
in University of Nottingham.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2018.07.022.
References
[1] B. Watzl, S. Girrbach, M. Roller, Inulin, oligofructose and immunomodulation, Br. J.
Nutr. 93 (Suppl 1) (2005) S49–S55.
[2] S. Miura, Y. Tsuzuki, R. Hokari, H. Ishii, Modulation of intestinal immune system by
dietary fat intake: relevance to Crohn's disease, J. Gastroenterol. Hepatol. 13 (1998)
1183–1190.
[3] J. Estaquier, B. Hurtrel, Mesenteric lymph nodes, a sanctuary for the persistance of
HIV. Escape mechanisms, Medecine Sciences: M/S, 24 2008, pp. 1055–1060.
[4] Y. Xie, T.R. Bagby, M.S. Cohen, M.L. Forrest, Drug delivery to the lymphatic system:
importance in future cancer diagnosis and therapies, Expert Opin. Drug Deliv. 6
(2009) 785–792.
[5] A. Zgair, J.B. Lee, J.C.M. Wong, D.A. Taha, J. Aram, D. Di Virgilio, J.W. McArthur,
Y.-K. Cheng, I.M. Hennig, D.A. Barrett, P.M. Fischer, C.S. Constantinescu,
P. Gershkovich, Oral administration of cannabis with lipids leads to high levels of
cannabinoids in the intestinal lymphatic system and prominent immunomodula-
tion, Sci. Rep. 7 (2017).
[6] N.S. Salemis, S. Gourgiotis, E. Tsiambas, G. Karagkiouzis, G. Nakos, V. Karathanasis,
Diﬀuse large B cell lymphoma of the mesentery: an unusual presentation and review
of the literature, J. Gastrointest. Cancer 40 (2009) 79–82.
[7] C.V. Fletcher, K. Staskus, S.W. Wietgrefe, M. Rothenberger, C. Reilly, J.G. Chipman,
G.J. Beilman, A. Khoruts, A. Thorkelson, T.E. Schmidt, J. Anderson, K. Perkey,
M. Stevenson, A.S. Perelson, D.C. Douek, A.T. Haase, T.W. Schacker, Persistent HIV-
1 replication is associated with lower antiretroviral drug concentrations in lym-
phatic tissues, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 2307–2312.
[8] W.N. Charman, C.J.H. Porter, Lipophilic prodrugs designed for intestinal lymphatic
transport, Adv. Drug Deliv. Rev. 19 (1996) 149–169.
[9] G.A. Edwards, C.J. Porter, S.M. Caliph, S.M. Khoo, W.N. Charman, Animal models
for the study of intestinal lymphatic drug transport, Adv. Drug Deliv. Rev. 50 (2001)
45–60.
[10] P. Gershkovich, A. Hoﬀman, Uptake of lipophilic drugs by plasma derived isolated
chylomicrons: linear correlation with intestinal lymphatic bioavailability, Eur. J.
Pharm. Sci. 26 (2005) 394–404.
[11] N.L. Trevaskis, W.N. Charman, C.J. Porter, Lipid-based delivery systems and in-
testinal lymphatic drug transport: a mechanistic update, Adv. Drug Deliv. Rev. 60
(2008) 702–716.
[12] N.L. Trevaskis, L.M. Kaminskas, C.J. Porter, From sewer to saviour - targeting the
lymphatic system to promote drug exposure and activity, Nat. Rev. Drug Discov. 14
(2015) 781–803.
[13] P. Gershkovich, B. Qadri, A. Yacovan, S. Amselem, A. Hoﬀman, Diﬀerent impacts of
intestinal lymphatic transport on the oral bioavailability of structurally similar
synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220, Eur. J. Pharm.
Sci. 31 (2007) 298–305.
[14] L. Hu, T. Quach, S. Han, S.F. Lim, P. Yadav, D. Senyschyn, N.L. Trevaskis,
J.S. Simpson, C.J. Porter, Glyceride-mimetic prodrugs incorporating self-im-
molative spacers promote lymphatic transport, avoid ﬁrst-pass metabolism, and
enhance oral bioavailability, Angew. Chem. Int. Ed. Eng. 55 (2016) 13700–13705.
[15] A. Zgair, J.C. Wong, J.B. Lee, J. Mistry, O. Sivak, K.M. Wasan, I.M. Hennig,
D.A. Barrett, C.S. Constantinescu, P.M. Fischer, P. Gershkovich, Dietary fats and
pharmaceutical lipid excipients increase systemic exposure to orally administered
cannabis and cannabis-based medicines, Am. J. Transl. Res. 8 (2016) 3448–3459.
[16] S. Han, T. Quach, L. Hu, A. Wahab, W.N. Charman, V.J. Stella, N.L. Trevaskis,
J.S. Simpson, C.J. Porter, Targeted delivery of a model immunomodulator to the
lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid pro-
drug strategies, J. Control. Release 177 (2014) 1–10.
[17] N. Borkar, B. Li, R. Holm, A.E. Hakansson, A. Mullertz, M. Yang, H. Mu, Lipophilic
prodrugs of apomorphine I: preparation, characterisation, and in vitro enzymatic
hydrolysis in biorelevant media, Eur. J. Pharm. Biopharm. 89 (2015) 216–223.
[18] J.K. Amory, G.K. Scriba, D.W. Amory, W.J. Bremner, Oral testosterone-triglyceride
conjugate in rabbits: single-dose pharmacokinetics and comparison with oral tes-
tosterone undecanoate, J. Androl. 24 (2003) 716–720.
[19] B.C. Lucey, J.W. Stuhlfaut, J.A. Soto, Mesenteric Lymph Nodes Seen at Imaging:
Causes and Signiﬁcance, Radiographics: A Review Publication of the, Vol. 25
Radiological Society of North America, Inc, 2005, pp. 351–365.
[20] P. Gershkovich, J. Fanous, B. Qadri, A. Yacovan, S. Amselem, A. Hoﬀman, The role
of molecular physicochemical properties and apolipoproteins in association of
drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylo-
microns, J. Pharm. Pharmacol. 61 (2009) 31–39.
[21] J. Stappaerts, S. Geboers, J. Snoeys, J. Brouwers, J. Tack, P. Annaert, P. Augustijns,
Rapid conversion of the ester prodrug abiraterone acetate results in intestinal su-
persaturation and enhanced absorption of abiraterone: in vitro, rat in situ and
human in vivo studies, Eur. J. Pharm. Biopharm. 90 (2015) 1–7.
[22] N. Fotaki, M. Vertzoni, Biorelevant dissolution methods and their applications in in
vitro-in vivo correlations for oral formulations, Open Drug Deliv. J., 4 (2010) 2–13.
[23] C.M. Parkinson, A. O'Brien, T.M. Albers, M.A. Simon, C.B. Cliﬀord, K.R. Pritchett-
Corning, Diagnostic necropsy and selected tissue and sample collection in rats and
mice, J. Visual. Exp. 54 (2011) 2966.
[24] L. Kagan, P. Gershkovich, A. Mendelman, S. Amsili, N. Ezov, A. Hoﬀman, The role
of the lymphatic system in subcutaneous absorption of macromolecules in the rat
model, Eur. J. Pharm. Biopharm. 67 (2007) 759–765.
[25] D.A. Taha, C.H. De Moor, D.A. Barrett, J.B. Lee, R.D. Gandhi, C.W. Hoo,
P. Gershkovich, The role of acid-base imbalance in statin-induced myotoxicity,
Transl. Res. 174 (2016) 140–160.
[26] D.A. Taha, A. Zgair, J.B. Lee, C.H. de Moor, D.A. Barrett, K.D. Bruce, M. Sungelo,
R.H. Eckel, P. Gershkovich, Hyperlipidaemia alone and in combination with
acidosis can increase the incidence and severity of statin-induced myotoxicity, Eur.
J. Pharm. Sci. 100 (2017) 163–175.
[27] M.E. Qazzaz, V.J. Raja, K.H. Lim, T.S. Kam, J.B. Lee, P. Gershkovich,
T.D. Bradshaw, In vitro anticancer properties and biological evaluation of novel
natural alkaloid jerantinine B, Cancer Lett. 370 (2016) 185–197.
[28] R.J. Tallarida, Quantitative methods for assessing drug synergism, Genes Cancer 2
(2011) 1003–1008.
[29] M.Y. Fanous, A.J. Phillips, J.A. Windsor, Mesenteric lymph: the bridge to future
management of critical illness, JOP 8 (2007) 374–399.
[30] G. Woodnutt, V. Berry, L. Mizen, Eﬀect of protein binding on penetration of beta-
lactams into rabbit peripheral lymph, Antimicrob. Agents Chemother. 39 (1995)
2678–2683.
[31] A.S. Borde, E.M. Karlsson, K. Andersson, K. Bjorhall, H. Lennernas, B. Abrahamsson,
Assessment of enzymatic prodrug stability in human, dog and simulated intestinal
ﬂuids, Eur. Pharm. Biopharm. 80 (2012) 630–637.
[32] S. Crauste-Manciet, D. Brossard, M.O. Decroix, R. Farinotti, J.C. Chaumeil,
Cefpodoxime-proxetil protection from intestinal lumen hydrolysis by oil-in-water
submicron emulsions, Int. J. Pharm. 165 (1998) 97–106.
[33] J.B. Lee, A. Zgair, T.H. Kim, M.G. Kim, S.D. Yoo, P.M. Fischer, P. Gershkovich,
Simple and sensitive HPLC-UV method for determination of bexarotene in rat
plasma, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1040 (2017) 73–80.
[34] K. Beaumont, R. Webster, I. Gardner, K. Dack, Design of ester prodrugs to enhance
oral absorption of poorly permeable compounds: challenges to the discovery sci-
entist, Curr. Drug Metab. 4 (2003) 461–485.
[35] V. Bala, S. Rao, P. Li, S. Wang, C.A. Prestidge, Lipophilic prodrugs of SN38:
synthesis and in vitro characterization toward oral chemotherapy, Mol. Pharm. 13
(2016) 287–294.
[36] A. Schafer, E.S. Burstein, R. Olsson, Bexarotene prodrugs: targeting through clea-
vage by NQO1 (DT-diaphorase), Bioorg. Med. Chem. Lett. 24 (2014) 1944–1947.
[37] L. Altucci, M.D. Leibowitz, K.M. Ogilvie, A.R. de Lera, H. Gronemeyer, RAR and
RXR modulation in cancer and metabolic disease, Nat. Rev. Drug Discov. 6 (2007)
793–810.
[38] M.I. Dawson, Z. Xia, The retinoid X receptors and their ligands, Biochim. Biophys.
Acta 1821 (2012) 21–56.
J.B. Lee et al. Journal of Controlled Release 286 (2018) 10–19
19
